24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
AXILIEVA 5MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | AXILIEVA 5MG |
|---|---|
| Composition | Axitinib Tablets 5 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
Axitinib Tablets 5 mg (Axitinib Tablets 5 mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
AXILIEVA 5MG (Axitinib Tablets 5 mg) is a targeted anticancer medicine used in the treatment of advanced kidney cancer (Renal Cell Carcinoma) and certain other oncology indications as prescribed by healthcare professionals. It contains Axitinib, a potent vascular endothelial growth factor receptor (VEGFR) inhibitor that helps slow the growth and spread of cancer cells by reducing the formation of new blood vessels that tumors need to survive and grow.
Cancer cells depend on a steady blood supply to receive oxygen and nutrients. Axitinib works by blocking specific receptors involved in angiogenesis, the process through which tumors create new blood vessels. By inhibiting these pathways, AXILIEVA 5MG helps restrict tumor growth and may contribute to better disease control in eligible patients.
Unlike conventional chemotherapy, Axitinib is a targeted therapy that focuses on molecular pathways associated with cancer progression. This precision-based approach allows oncologists to manage certain cancers more effectively while supporting individualized treatment strategies.
AXILIEVA 5MG is commonly prescribed for:
• Advanced Renal Cell Carcinoma (RCC)
• Metastatic Kidney Cancer
• Targeted Oncology Treatment Programs
• Combination Immunotherapy Protocols
• Long-Term Cancer Management
• Advanced Solid Tumor Treatment Under Specialist Guidance
The medicine may be used alone or in combination with other anticancer therapies depending on the patient’s diagnosis, treatment history, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, AXILIEVA 5MG is designed to deliver reliable therapeutic performance and consistent product quality. The medicine should only be used under the supervision of qualified oncologists and healthcare professionals experienced in cancer treatment.
Patients receiving Axitinib therapy may require regular monitoring of blood pressure, liver function, kidney function, thyroid function, and overall treatment response. These evaluations help optimize treatment outcomes and manage potential side effects effectively.
Due to its effectiveness in targeted oncology care, AXILIEVA 5MG has become an important component of modern kidney cancer treatment protocols and precision cancer therapy programs.
AXILIEVA 5MG (Axitinib Tablets 5 mg) is primarily used for the treatment and management of specific cancers.
AXILIEVA is widely used in the treatment of advanced kidney cancer and helps slow disease progression.
Doctors may prescribe Axitinib for patients whose kidney cancer has spread to other parts of the body.
The medicine is used as part of precision oncology treatment plans aimed at targeting specific cancer growth pathways.
AXILIEVA may be used alongside immunotherapy medicines or other targeted therapies as recommended by oncologists.
The medicine supports ongoing cancer control and may help improve treatment outcomes in eligible patients.
Axitinib is commonly included in advanced cancer treatment protocols in specialized oncology centers.
Axitinib belongs to a class of medicines known as VEGFR (Vascular Endothelial Growth Factor Receptor) inhibitors.
AXILIEVA works by:
• Blocking VEGF receptors
• Reducing tumor blood vessel formation
• Limiting nutrient supply to cancer cells
• Slowing cancer growth
• Inhibiting tumor progression
• Supporting targeted oncology treatment
This mechanism helps control cancer development and supports long-term disease management.
Like other targeted cancer medicines, AXILIEVA 5MG may cause side effects in some patients. Side effects vary depending on treatment duration, overall health, and individual response.
Elevated blood pressure is one of the most frequently reported side effects of Axitinib.
Patients may experience weakness, tiredness, or reduced energy levels.
Digestive disturbances and loose stools may occur during treatment.
Some patients may experience decreased appetite and reduced food intake.
Mild nausea or stomach discomfort may develop during therapy.
Gradual weight loss may occur in some individuals.
Changes in voice quality or hoarseness may be observed during treatment.
Redness, tenderness, pain, or peeling of the hands and feet may occur.
Mild to moderate headaches may develop during therapy.
Although uncommon, certain side effects require immediate medical attention.
• Severe chest pain
• Difficulty breathing
• Severe bleeding
• Persistent high blood pressure
• Sudden vision changes
• Severe abdominal pain
• Signs of liver problems
• Severe allergic reactions
• Blood clots or stroke-like symptoms
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of AXILIEVA 5MG (Axitinib Tablets 5 mg) should always be determined by a qualified healthcare professional based on the patient’s medical condition and treatment response.
Treatment requirements vary depending on the specific cancer diagnosis and disease stage.
Age, body weight, organ function, and general health influence dosage decisions.
Doctors may adjust dosage depending on blood pressure levels during treatment.
Patients with liver impairment may require special monitoring and dosage modifications.
Dosage adjustments may be made based on effectiveness and side effect management.
• Take the tablet exactly as prescribed.
• Swallow the tablet whole with water.
• Do not crush, chew, or break the tablet.
• Take the medicine at the same time every day.
• Follow all medical instructions carefully.
• Do not discontinue treatment without consulting your doctor.
Regular monitoring is important throughout treatment.
Before starting treatment, patients should inform their doctor if they have:
• High blood pressure
• Heart disease
• Liver disorders
• Kidney problems
• Bleeding disorders
• Thyroid disease
• Previous cancer treatment complications
Patients should also disclose all medications, supplements, and herbal products currently being used to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Advanced targeted cancer therapy
• Effective VEGFR inhibitor formulation
• Supports kidney cancer treatment
• Trusted oncology treatment option
• Manufactured under strict pharmaceutical quality standards
• Suitable for modern precision oncology protocols
• Reliable long-term disease management support
It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and related oncology conditions.
Axitinib is a targeted anticancer medicine that blocks VEGF receptors to help slow tumor growth.
No, it is a targeted therapy medicine that works differently from traditional chemotherapy.
Yes, Axitinib is designed to reduce blood vessel formation in tumors and help control cancer growth.
Yes, elevated blood pressure is a common side effect and should be monitored regularly during treatment.
Yes, doctors usually recommend blood pressure checks, laboratory tests, and routine medical assessments throughout treatment.
No, treatment should only be stopped under the guidance of a healthcare professional.
Yes, this medicine should always be used under the supervision of qualified healthcare professionals experienced in oncology care.